Business
VERTEX PHARMACEUTICALS INC / MA: We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label.
Revenue increased 8.9% to $12.00B, while Net income increased 838.1% to $3.95B.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $12.00BOK
- Profitability — Net income $3.95BOK
- Cash generation — Free cash flow $3.19BOK
- Accounting — Formula-grey distress score · no manipulation flag · earnings quality not computedNote
- Insiders — 0 buys; 46 sells in 365 daysNote
- Capital — share repurchases were $2.02BNote
Where the revenue comes from
Fiscal 2025, as VERTEX PHARMACEUTICALS INC / MA reports it. History and quarterly detail are in the app.
- Product revenues, net$12.0B
- CASGEVY$115.8M
- JOURNAVX$59.6M
- Other revenues$30.7M
Leadership changes
From VERTEX PHARMACEUTICALS INC / MA's own filings, the day they're filed.
- Suketu Upadhyay · directors · departureeff. 2026-04-28
- Vertex Pharmaceuticals Incorporated · director · departureeff. 2026-04-28
- Nancy Thornberry · member of the board of directors · appointmenteff. 2023-12-05
Latest filings
- 8-K · Company announcement2026-09-01
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-07
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about VERTEX PHARMACEUTICALS INC / MA, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.